Organization | Marino Biotechnology Co., Ltd.

Marino Biotechnology Co., Ltd. Report issue

For profit Phase 1

Founded: Beijing China (2015)

Organization Overview

First Clinical Trial

2016

NCT02842138

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Alternative names

Marino Biotechnology Co., Ltd.

Active Ingredients

Drugs in Phase 1 Trials (7)

autologous chimeric switch receptor modified t cells (1 trial)

autologous csr t (1 trial)

cd19 car-t cells (2 trials)

cyclophosphamide (cytoxan) (1 trial)

egfrviii car t cells (1 trial)

fludarabine (fludara) (1 trial)

mesothelin car t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Glioblastoma (Phase 1)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Neoplasms (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 6
# of Trial APIs: 7